View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 6, 2018updated 12 Jul 2022 1:13pm

Nicox starts Phase ll trial of NCX 470 against latanoprost 0.005%

Nicox has commenced a Phase ll clinical trial to examine the efficacy and safety of NCX 470 in comparison with latanoprost 0.005% for the treatment of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Nicox has commenced a Phase ll clinical trial to examine the efficacy and safety of NCX 470 in comparison with latanoprost 0.005% for the treatment of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The multi-centre, double-masked, 28-day, parallel group dose-ranging trial has already enrolled ten patients.

During the trial, 420 patients are expected to randomise in various clinical sites across the US.

The trial’s primary endpoint is the mean reduction in diurnal IOP after four weeks of treatment, and its overall objective is to identify the appropriate dose of NCX 470 for Phase lll studies of the drug.

Top-line results from the trial are scheduled to be available by the second half of next year.

“We believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients.”

Nicox chairman and CEO Michele Garufi said: “Based on our preclinical data, we believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients.

“The development of NCX 470 is testimony to the power of our efforts fuelled by the seamless collaboration between our US and European R&D teams, and follows on the back of the Food and Drug Administration (FDA) approval of our first-generation NO-donating compound VYZULTA, commercialised in the US since last December by our partner Bausch + Lomb.”

NCX 470 is a novel chemical entity developed as an ophthalmic solution of the new, second-generation nitric oxide (NO)-donating prostaglandin analogue for reducing IOP in patients with open-angle glaucoma and ocular hypertension.

Glaucoma is a group of ocular diseases which damages the optic nerve, thereby leading to peripheral and, ultimately, central visual field loss.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena